Article · Wikipedia archive · Last revised Jun 23, 2026

BFAI

BFAI, also known as 5,6-benzofuranyl-2-aminoindane, is a drug of the 2-aminoindane family that acts as a serotonin releasing agent (SSRA) and may produce entactogenic effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran. The drug was patented by Matthew Baggott and Tactogen in 2022.

Last revised
Jun 23, 2026
Read time
≈ 1 min
Length
123 w
Citations
2
Source
Wikipedia ↗
BFAI
Clinical data
Other names5,6-Benzofuranyl-2-aminoindane; 5,6-Benzofuranyl-2-aminoindan
Drug classSelective serotonin releasing agent; Entactogen
ATC code
  • None
Identifiers
  • 6,7-dihydro-5H-cyclopenta[f][1]benzofuran-6-amine
CAS Number
PubChem CID
Chemical and physical data
FormulaC11H11NO
Molar mass173.215 g·mol−1
3D model (JSmol)
  • C1C(CC2=C1C=C3C=COC3=C2)N
  • InChI=1S/C11H11NO/c12-10-4-8-3-7-1-2-13-11(7)6-9(8)5-10/h1-3,6,10H,4-5,12H2
  • Key:SYCRQDBZPIEBIR-UHFFFAOYSA-N

BFAI, also known as 5,6-benzofuranyl-2-aminoindane, is a drug of the 2-aminoindane family that acts as a serotonin releasing agent (SSRA) and may produce entactogenic effects in humans, which may be useful for psychotherapeutic applications. It is closely related to MDAI but with the benzodioxole ring system replaced by benzofuran.1 The drug was patented by Matthew Baggott and Tactogen in 2022.1

See also

See also

References

References

  1. WO 2022/032147, Baggott M, "2-Aminoindane compounds for mental disorders or enhancement.", published 10 February 2022, assigned to Tactogen Inc. 
External links